Introduction
============

Premature ovarian failure (POF) is a disease characterized by amenorrhoea, infertility, estrogen deficiency, reduced follicles and elevated gonadotropin prior to the age of 40 years ([@b1-etm-0-0-5970],[@b2-etm-0-0-5970]). POF occurs in 1--3% of women, and its incidence rate has demonstrated an increasing tendency in recent years ([@b3-etm-0-0-5970],[@b4-etm-0-0-5970]). Women suffering from POF may have an increased risk of osteoporosis, cardiovascular disease and dementia ([@b5-etm-0-0-5970]). Furthermore, it has been reported that POF may lead to a series of health problems, such as depression, anxiety as well as compromised quality of marital life and sexual function ([@b6-etm-0-0-5970]). The etiology of POF is complex, and remains to be fully elucidated, but it has been reported to be associated with factors including autoimmune responses, infection, genetic factors, iatrogenic effects of treatments such as chemotherapy, radiotherapy and surgery, and endocrine dysfunction ([@b7-etm-0-0-5970],[@b8-etm-0-0-5970]). At present, management of POF essentially involves hormone replacement and infertility treatment, particularly hormone replacement therapy (HRT), which is considered as the clinical treatment of choice ([@b9-etm-0-0-5970],[@b10-etm-0-0-5970]). However, HRT does not fundamentally restore normal ovarian function. In addition, a study has demonstrated that HRT may increase the risk of breast cancer ([@b10-etm-0-0-5970]). Therefore, novel therapeutic strategies that restore ovarian function of patients with POF are required.

Stem cell therapy has been identified as a potential and alternative therapeutic means of potentially repairing and restoring the normal function of damaged tissues, presenting a novel approach for clinical treatment of POF ([@b11-etm-0-0-5970]). Previous pre-clinical studies have revealed that the transplantation of stem cells into animal models of POF restores ovarian function and generates immature oocytes ([@b12-etm-0-0-5970],[@b13-etm-0-0-5970]). However, research on stem cell transplantation for the treatment of POF is mostly limited to preliminary animal experiments. As such, clinical studies have rarely been reported ([@b14-etm-0-0-5970]--[@b16-etm-0-0-5970]) and there is a lack of systematic pre-clinical studies providing a sufficiently large sample to confirm the safety and efficacy of stem cell treatment. The aim of the present study was to perform a systematic review and meta-analysis of stem cell treatment in animal models of POF, and to provide a further proof-of-concept for the clinical treatment of POF ([@b17-etm-0-0-5970],[@b18-etm-0-0-5970]).

Furthermore, the present study reported on a case of POF treated by autologous MSCs transplantation in order to demonstrate that stem cell transplantation may elicit the same clinical effects in patients as in animal models of POF.

Materials and methods
=====================

### Ethics statement

The case report in the present study was performed with the informed consent of the patient according to the Declaration of Helsinki and was approved by the Society of Medical Ethics of Jiangsu Province (Nanjing, China). The patient agreed for ultrasound and scanning images to be published in the present study.

### Literature search

A systematic search was performed to identify all studies on stem cell therapy in animal models of POF using electronic databases (PubMed, Embase and the Cochrane Library) published until up to June 2016. The key words used for relevant literature searches were 'stem cell', 'cytotherapy', 'premature ovarian failure' and 'premature ovarian insufficiency', and search results were limited to studies in English language. In addition, relevant studies were also identified by manual searching of the reference lists of all relevant articles and previous review articles.

### Inclusion and exclusion criteria

Studies were included if they met all of the following criteria: i) Full-text articles; ii) randomized or a case control studies; iii) POF or premature ovarian insufficiency (POI) animal models; iv) animal models of POF or POI were assigned to a group of topical or systemic therapy with stem cells or a control group (without stem cells); and v) one of the following outcomes was included: Follicle-stimulating hormone (FSH), estradiol (E2), ovarian weight, the number of pregnancies and follicle count.

Studies were excluded according to the following criteria: i) No randomized or case control study as they are rare; ii) studies with incomplete reporting of data or insufficient sample size; iii) studies that were duplicates of included studies; iv) non-English literature; v) studies utilizing stem cell factor; vi) no inclusion of the desired outcomes; vii) studies on animal models of POF which also had other diseases; and viii) reviews, editorials, non-animal studies, letters and conference papers without sufficient data.

### Data extraction

Data including first author name, country, publication year, study design (randomized or case control), source and type of stem cells, species of animals, details of the animal model, route of delivery, number of stem cells and time of transplantation, intervention methods, follow-up duration, as well as the major outcome measures were extracted from each included study by two independent authors (S.G. and L.C.). For articles only reporting data as figures, the values of mean and standard deviation (SD) or standard error (SE) were extracted from images by two independent authors.

### Case report

A 38-year-old woman was diagnosed with POF due to chronic usage of hormone drug treatment for polycystic ovary syndrome. The major clinical symptoms in the patient were amenorrhea for 2 years, accompanied by hectic fever and sweating, soreness and weakness of waist and knees and vaginal dryness. Review of medical history, physical examination and laboratory tests were performed prior to the cell therapy. The patient had no remarkable family and medical history. Laboratory tests revealed persistently high serum FSH and luteinizing hormone (LH) levels, as well as low E2 levels, consistent with POF. Prior to the treatments, it was explained to the patient that the treatment was experimental; the patient\'s informed consent was obtained. With approval of the Society of Medical Ethics of Jiangsu Province, the patient with POF was scheduled for autologous MSC transplantation ([@b19-etm-0-0-5970]). The patient began to receive MSC treatments on January 4, 2014, and the total number of treatments was 6 (one treatment per month). The patient was transplanted with MSCs (100 ml 0.9% normal saline, at a concentration of 2×10^7^ cells/ml for the first time and at a concentration of 1×10^7^/ml for the latter 5 times) by intravenous injection. After MSC therapy, the patient was subjected to transvaginal ultrasound (TVS) and transabdominal ultrasound (TAS) detection on March 6, May 15 and July 24, 2014, respectively. In addition, transvaginal color Doppler flow imaging (CDFI) also was performed to assess the endometrial blood flow.

### Statistical analysis

For each outcome measure, the sample size as well as mean value and standard deviation were recorded for the treatment groups and control groups. The effect size of stem cell therapy was calculated, and standardized mean difference (SMD) with 95% confidence intervals (CIs) was used for analysis of continuous data, whereas dichotomous data were presented as risk ratios (RRs) with 95% CIs. The heterogeneity among the studies was assessed by using Cochrane\'s Q test and I^2^ statistics, and I^2^\>50% was considered indicative of a significant heterogeneity ([@b20-etm-0-0-5970]). A random-effects model was used to estimate the pooled results instead of a fixed-effects model, to minimize the influence of potential heterogeneity between the studies. A sensitivity analysis was performed to evaluate the stability of the results by subsequently excluding individual studies. Subgroup analyses and meta-regression were performed to assess the impact of certain study characteristics on the outcomes and to reveal potential sources of heterogeneity. In addition, potential publication bias was evaluated by funnel plot, Egger\'s test and Begg\'s test ([@b21-etm-0-0-5970]). A non-parametric 'trim-and-fill' analysis was also performed to further evaluate the possible effect of publication bias on the results of the meta-analysis. A two-sided P-value \<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed by using Stata software (version 12.0; Stata, College Station, TX, USA).

Results
=======

### Search results and characteristics of included studies

In [Fig. 1](#f1-etm-0-0-5970){ref-type="fig"}, a flow diagram illustrating the study selection procedure is presented. A total of 297 studies were retrieved after initial search of the databases. Among these, 254 articles were excluded by screening the titles and abstracts, mainly due to being irrelevant to the objective of the study, or due to being literature reviews or duplicate reports. The remaining 43 articles underwent a more detailed evaluation. Among those articles, 5 did not involve animal models of POF, 11 did not have any full-text version available online, 1 was not written in English, 3 were duplicates of another study, 3 did not provide the appropriate outcomes, 1 study compared two types of cells from different sources, and 3 studies did not provide the sample size for E2 or the follicle count. Finally, 16 studies ([@b12-etm-0-0-5970],[@b22-etm-0-0-5970]--[@b36-etm-0-0-5970]) were included in the meta-analysis, whose details are presented in [Table I](#tI-etm-0-0-5970){ref-type="table"}.

Among the included studies, 13 were from China ([@b12-etm-0-0-5970],[@b23-etm-0-0-5970]--[@b28-etm-0-0-5970],[@b30-etm-0-0-5970]--[@b35-etm-0-0-5970]), one was from Egypt ([@b22-etm-0-0-5970]), one was from Turkey ([@b29-etm-0-0-5970]) and one was from the United States ([@b36-etm-0-0-5970]). In the animal models, POF was mainly induced by chemotherapy (15 studies) ([@b12-etm-0-0-5970],[@b22-etm-0-0-5970],[@b26-etm-0-0-5970]--[@b28-etm-0-0-5970],[@b32-etm-0-0-5970]--[@b36-etm-0-0-5970]) and Gr cobalt 60 γ ([@b11-etm-0-0-5970])-ray irradiation (1 study) ([@b26-etm-0-0-5970]). Among these 16 studies, 1 reported four outcome measures ([@b12-etm-0-0-5970]), 7 reported three outcome measures ([@b22-etm-0-0-5970]--[@b24-etm-0-0-5970],[@b26-etm-0-0-5970],[@b28-etm-0-0-5970],[@b33-etm-0-0-5970],[@b35-etm-0-0-5970]), 1 reported two outcome measures ([@b30-etm-0-0-5970]) and 7 reported only one outcome measure ([@b25-etm-0-0-5970],[@b27-etm-0-0-5970],[@b29-etm-0-0-5970],[@b31-etm-0-0-5970],[@b32-etm-0-0-5970],[@b34-etm-0-0-5970],[@b36-etm-0-0-5970]). The stem cells used in the treatment group included human umbilical cord MSCs, adipose-derived stem cells, ovarian granulosa-like cells derived from human-induced pluripotent stem cells (PSCs), human amniotic epithelial cells, human cord blood mononuclear cells, human endometrial MSCs, bone marrow-derived MSCs, skin-derived MSCs and microRNA-17-3p-transfected human-induced PSCs, with the total numbers of the transplanted cells ranging from 1×10^3^ to 3×10^7^. In particular, Song *et al* ([@b23-etm-0-0-5970]), Zhang *et al* ([@b25-etm-0-0-5970]), Kilic *et al* ([@b29-etm-0-0-5970]), Wang *et al* ([@b32-etm-0-0-5970]) and Fu *et al* ([@b35-etm-0-0-5970]) included multiple comparisons with various stages of the follicles and Song *et al* ([@b23-etm-0-0-5970]) included multiple comparisons with different delivery routes of stem cells. Lai *et al* ([@b31-etm-0-0-5970]) included comparisons with different sources of stem cells. All of these comparisons were included in the meta-analysis. Overall, it contained 59 comparisons, with 724 animals for the stem cell treatment group, and 660 animals for the control group. The follow-up duration of these studies varied from 2 to 8 weeks ([Table I](#tI-etm-0-0-5970){ref-type="table"}).

### Meta-analysis

The major outcomes for the eligible studies were the levels of FSH and E2, ovarian weight, follicle count and the number of pregnancies. A random-effects model instead of a fixed-effects model was used for assessing the effect size of stem cells on FSH, E2, ovarian weight and follicle count due to significant heterogeneity, while a fixed-effect models was adopted for the analysis of the number of pregnancies. The pooled analysis suggested that stem cell transplantation led to a statistically significant improvement in FSH \[SMD=−1.330; 95% CI, -(2.095--0.565); Z=3.41, degrees of freedom (df)=7; P=0.001; [Fig. 2](#f2-etm-0-0-5970){ref-type="fig"}\], E2 (SMD=2.334; 95% CI, 1.350--3.319; Z=4.65; df=10; P\<0.001; [Fig. 3](#f3-etm-0-0-5970){ref-type="fig"}), ovarian weight (SMD=1.310; 95% CI, 0.157--2.463; Z=2.23; df=2; P=0.026; [Fig. 4](#f4-etm-0-0-5970){ref-type="fig"}), follicle count (SMD=1.871; 95% CI, 1.226--2.5160; Z=5.69; df=31; P\<0.001; [Fig. 5](#f5-etm-0-0-5970){ref-type="fig"}), as well as the number of pregnancies (RR=1.715; 95% CI, 1.213--2.424; Z=3.05; df=3; P=0.002; [Fig. 6](#f6-etm-0-0-5970){ref-type="fig"}) as compared with those in the control group. In addition, no heterogeneity in the meta-analysis of the number of pregnancies was noted (I^2^=0%; χ^2^=1.01; P=0.798), but there was a significant heterogeneity in the meta-analysis of FSH (I^2^=82.8%; χ^2^=40.79; P\<0.001), E2 (I^2^=90.0%; χ^2^=99.89; P\<0.001), ovarian weight (I^2^=78.6%; χ^2^=9.36; P=0.009) and follicle count (I^2^=90.0%; χ^2^=310.53; P\<0.001).

### Subgroup analyses and meta-regression

In order to investigate the source of the heterogeneity of the results, subgroup analyses of the included trails were performed based on study design, cell type, details of the animal model, different units of FSH, stages of the follicles and the route of stem cell delivery to assess their impact on the primary outcomes of FSH, E2 and follicle count ([Table II](#tII-etm-0-0-5970){ref-type="table"}). For the amounts of stem cells delivered and the follow-up duration, a meta regression analysis was performed. Of note, the present study did not perform any subgroup analyses or meta regression for ovarian weight and the number of pregnancies based on the above baseline characteristics, as only 3--4 comparisons had been included. The results of the subgroup analyses or multivariate meta-regression demonstrated that study design, cell type, units of FSH, follicle stage, the follow-up duration, the route of delivery and amount of stem cells, as well as details of the animal model, were not the cause of the heterogeneity of the results on FSH, E2 and follicle count in animal models of POF treated with stem cells.

### Sensitivity analyses and publication bias

To evaluate the robustness of the estimated pooled effect size for FSH, E2, ovarian weight, follicle count and the number of pregnancies, the present study performed a sensitivity analysis by sequentially excluding one study at a time and recalculating the pooled effect size of the remaining studies. The results of sensitivity analyses revealed that none of the individual studies appeared to impact the overall results on FSH, E2, ovarian weight, follicle count and the number of pregnancies in animal models of POF based on the stem cell therapy, which suggested that the pooled effect on FSH, E2, ovarian weight, follicle count and the number of pregnancies was stable (data not shown).

The funnel plots for the effects of stem cell therapy on E2 and follicle count were asymmetrical on visual inspection, indicating that possible publication bias may have existed between the eligible studies ([Figs. 7](#f7-etm-0-0-5970){ref-type="fig"} and [8](#f8-etm-0-0-5970){ref-type="fig"}, respectively). Consistently, the results of Egger\'s and Begg\'s tests also demonstrated the existence of potential publication bias (for E2, P=0.039 and 0.008 for Egger\'s and Begg\'s test, respectively; for follicle count, P=0.028 and 0.046 for Egger\'s and Begg\'s test, respectively). Subsequently, a 'trim-and-fill' analysis was performed by imputing five and nine hypothetical negative unpublished studies for E2 and follicle count, respectively, with the aim of producing a symmetrical funnel plot. The pooled effect size including the hypothetical studies under the random-effects model remained statistically significant in favor of stem cells for E2 (16 comparisons; SMD=2.71; 95% CI, 0.90--8.21) and follicle count (41 comparisons; SMD=2.27; 95% CI, 1.10--4.69). In addition, no potential publication bias was noted for FSH based on visual inspection of the funnel plot ([Fig. 9](#f9-etm-0-0-5970){ref-type="fig"}), which was consistent with the results of Egger\'s test (P=0.760) and Begg\'s test (P=0.536). However, the publication bias among studies on the effects of stem cell therapy on ovarian weight and the number of pregnancies were difficult to assess, as only three to four studies were available for each comparison.

### Case report results

After MSC treatment, TVS and TAS imaging indicated that the size of the ovaries and the endometrial thickness were improved. On March 6, 2014, the sizes of the left and right ovary were 1.9×1.3 and 2.2×1.0 cm, respectively. On May 15, 2014, the sizes of the left and right ovary were 2.3×1.6 and 2.3×1.9 cm, respectively. On July 24, 2014, the sizes of the left and right ovary were 3.3×2.0 and 2.7×1.2 cm, respectively. The endometrial thickness was 0.3, 0.6 and 0.75 cm on March 6, May 15, and July 24, 2014, respectively. No abnormal echo was found in the parenchyma. Of note, the results of CDFI on July 24, 2014 suggested abundant blood flow signals in the patient\'s uterus. Endometrial morphology and size of ovary on March 6 and May 15, 2014 are presented in [Figs. 10](#f10-etm-0-0-5970){ref-type="fig"} and [11](#f11-etm-0-0-5970){ref-type="fig"}, respectively. Endometrial morphology and blood flow on July 24, 2014 are presented in [Fig. 12](#f12-etm-0-0-5970){ref-type="fig"}.

Discussion
==========

The etiology of POF is complex and may be caused by numerous factors, such as genetic defects, autoimmune reactions, chemotherapy, radiotherapy and surgery. At present, no effective treatment for POF is currently available. Stem cells, as a multipotent cell type with the capacity of self-renewal and multilineage differentiation, have been proposed as a promising tool in tissue engineering for regenerative medicine ([@b37-etm-0-0-5970]). Their therapeutic potential has provided a novel strategy for preserving or recovering damaged ovarian function of women who receive chemotherapy or radiotherapy. Previous studies on animal models have revealed a favorable effect of stem cell-based therapy on POF caused by chemotherapy, radiotherapy or other etiologies ([@b25-etm-0-0-5970],[@b26-etm-0-0-5970]). However, to the best of our knowledge, those studies lack quantitative evaluation of the results and no randomized controlled trial in humans has currently been published. Therefore, a meta-analysis of animal studies was performed to assess the effects of stem cell therapy for POF and to describe the case report in the present study.

In the present meta-analysis, FSH, E2, follicle count, ovary weight and the number of pregnancies were selected as the outcome of interest, as they are known to correlate well with ovarian function recovery after POF, and are considered as reliable predictors for the risk of POF in women ([@b38-etm-0-0-5970],[@b39-etm-0-0-5970]). The observed improvement of FSH, E2, follicle count, ovary weight and the number of pregnancies after stem cell transplantation strongly indicated a favorable therapeutic effect of stem cells on POF. Specifically, the result of the present meta-analysis indicated that stem cell transplantation was associated with a significant improvement of ovarian function in animal models of POF, by improving the weight of ovaries, restoring fertility and the number of pregnancies and balancing the level of serum sex hormones (FSH and E2), which demonstrated the potential of stem cell-based therapies for treating POF. These improvements may be attributed to the differentiation, homing and paracrine function of stem cells. The proposed mechanisms via which stem cells repair the damaged ovarian function in POF include the following: i) Stem cells migrate into injured ovarian tissue and differentiate into ovarian tissue-like cells, particularly into granulosa cells, which are an essential component of the ovarian micro-environment and have a key role in regulating reproductive ovarian physiology, including ovulation and luteal regression ([@b25-etm-0-0-5970]); ii) stem cells may home to and reside in ovarian tissue and help to improve the damaged ovarian niches by secreting a number of angiogenic growth factors, such as hepatocyte growth factor, vascular endothelial growth factor, placental growth factor and transforming growth factor-β ([@b23-etm-0-0-5970],[@b40-etm-0-0-5970]); and iii) stem cell transplantation effectively alleviates the chemotherapy-induced inflammatory reaction in ovarian tissue via secretion of anti-inflammatory factors ([@b25-etm-0-0-5970]). These mechanisms support that stem cell therapy is beneficial for the improvement of ovarian function in subjects with POF.

In spite of stem cell therapy having been identified to have significant beneficial pooled effects on each outcome measure, a considerable degree of heterogeneity was observed in the estimates of the present study. Thus, subgroup analyses and meta regression were performed to estimate potential sources of the heterogeneity. Based on this analysis, it was found that study design, cell type, different units of FSH, stage of the follicles, details of the animal models, the amount and route of administration of stem cells and the follow-up duration were not the causes of the heterogeneity of the results for FSH, E2 and follicle count. Of note, however, among the 16 trails included, only one study assessed stem cell therapy in animal models of POF induced by radiotherapy, while all others used animals of POF induced by chemotherapy. Therefore, there may be a non-negligible difference in the therapeutic effects of POF between chemotherapy and radiotherapy, and further research is required to confirm this observation. In addition, studies have demonstrated that the degree of ovarian damage induced by chemotherapy and radiotherapy is dependent on factors such as the dose, drug type, patient age and the radiation therapy field ([@b39-etm-0-0-5970],[@b41-etm-0-0-5970],[@b42-etm-0-0-5970]). Among the studies included in the present meta-analysis, the dose of chemotherapeutic drugs or radiation dose, drug type, as well as the age of the animals were different in each study. In addition, to date, it has remained to be determined which specific approach of assessing the therapeutic effect of stem cell-based therapy on POF induced is most favorable with regard to induction by chemotherapy or radiotherapy. Therefore, although the effect of stem cells in the treatment of POF was systematically evaluated by the present study, certain potential limitations remained, which should be considered when interpreting the results. First, the present study confirmed that stem cell-based therapy effectively improves ovarian function in animal models of POF through reducing the levels of FSH, elevating the levels of E2, restoring the fertility of animals, as well as promoting the formation of follicles, but the significant heterogeneity among the included studies should be considered. Furthermore, although subgroup analyses and meta regression suggested that the abovementioned baseline characteristics were not the causes of heterogeneity, the heterogeneity may have been due to the limited number of studies included for each outcome. Hence, large-scale studies based on the above classification features are required in the future. In addition, FSH, E2, ovary weight, follicle count and the number of pregnancies were selected as the outcomes of interest, but whether stem cell-based therapy confers other benefits, such as improvement in the estrous cycle of animals or LH, remains elusive and deserves further study. Furthermore, few studies have considered measuring ovary weight, and it was therefore not possible to determine the heterogeneity of the results of ovarian weight. Therefore, future large-scale, high-quality studies are required to determine what causes the heterogeneity of the results of ovarian weight. In addition, a great variety of stem cell types were included, and the therapeutic effect of stem cells from different sources in POF may be different; therefore, their influence on the accuracy of the results cannot be ignored. Finally, indications of publication bias were identified, which may have impacted the results of the present meta-analysis; this is a common phenomenon that usually affects meta-analyses of animal studies, as those studies with positive results are more likely to be published. In view of this problem, the present study performed a 'trim and fill' procedure via hypothetically imputing unpublished studies with negative results. It was found that the pooled results were not significantly influenced by the publication bias based on 'trim and fill' analysis.

Of note, stem cell-based therapy is also capable of improving the ovarian function of the patient with POF who was the subject of the present case report. After MSC therapy, the sizes of the ovaries returned to normal and the endometrial thickness was increased, along with rich endometrial blood flow, suggesting that stem cell therapy may be an effective therapeutic strategy for the treatment of POF. However, regarding the case study of the present study, certain limitations require discussing. First, the patient was not monitored for folliculogenesis by B ultrasound. Furthermore, the ovarian function was not further evaluated through the detection of serum hormone levels (FSH, E2, LH). In addition, the participant was not followed up long-term to observe the recovery of menstruation. Therefore, further and deeper investigation is required to better confirm the efficacy of stem cell transplantation in patients with POF. The present case report was a study of level 4 evidence according to evidence-based medicine ([@b43-etm-0-0-5970]), but the results were positive; furthermore, a prospective study has reported that stem cell transplantation not only resulted in improvement of the hormonal profile of a POF patient but also in the resuming of menstruation and the occurrence of pregnancy, resulting in the delivery of a full-term healthy infant ([@b10-etm-0-0-5970]). This result was indicative of a good clinical outcome. For this reason, clinical randomized controlled trial studies are required in the future.

In conclusion, the results of the present meta-analysis illustrated that stem cell transplantation into animal models of POF significantly improved the ovarian function as compared with that of untreated controls. These results combined with the present case report demonstrated that stem cell-based strategies may become a potential therapy for POF.
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![Forest plot demonstrating the effect of stem cell therapy on follicle stimulating hormone improvement compared with controls. SMD, standardized mean difference; CI, confidence interval; SD, standard deviation; ITV, intra-tail venous.](etm-15-05-4105-g01){#f2-etm-0-0-5970}

![Forest plot presenting the effect of stem cell therapy on estradiol improvement compared with controls. SMD, standardized mean difference; CI, confidence interval; SD, standard deviation; ITV, intra-tail venous.](etm-15-05-4105-g02){#f3-etm-0-0-5970}

![Forest plot presenting the effect of stem cell therapy on ovarian weight improvement compared with controls. SMD, standardized mean difference; CI, confidence interval; SD, standard deviation; ITV, intra-tail venous.](etm-15-05-4105-g03){#f4-etm-0-0-5970}

![Forest plot illustrating the effect of stem cell therapy on follicles count improvement compared with controls. SMD, standardized mean difference; CI, confidence interval; SD, standard deviation; ITV, intra-tail venous.](etm-15-05-4105-g04){#f5-etm-0-0-5970}

![Forest plot presenting the effect of stem cell therapy on the number of pregnancy improvement compared with controls. RR, risk ratio; CI, confidence interval; SD, standard deviation; ITV, intra-tail venous.](etm-15-05-4105-g05){#f6-etm-0-0-5970}

![Funnel plot of the SMD for estradiol in animal models of premature ovarian failure assigned to the stem cell-based therapy or control groups. SMD, standardized mean difference.](etm-15-05-4105-g06){#f7-etm-0-0-5970}

![Funnel plot of the SMD for follicle count of premature ovarian failure in animal models of premature ovarian failure assigned to the stem cell-based therapy or control groups. SMD, standardized mean difference.](etm-15-05-4105-g07){#f8-etm-0-0-5970}

![Funnel plot of the SMD for follicle-stimulating hormone in animal models of premature ovarian failure assigned to the stem cell-based therapy or control groups. SMD, standardized mean difference.](etm-15-05-4105-g08){#f9-etm-0-0-5970}

![Transabdominal ultrasound and transvaginal ultrasound detection of endometrial morphology on March 6, 2014. The (A) endometrial thickness was 0.3 cm and, sizes of (B) right and (C) left ovary were 2.2×1.0 and 1.9×1.3 cm, respectively.](etm-15-05-4105-g09){#f10-etm-0-0-5970}

![Transabdominal ultrasound and transvaginal ultrasound detection of endometrial morphology on May 15, 2014. (A) The endometrial thickness was 0.6 cm. The sizes of (B) right and (C) left ovary were 2.3×1.9 and 2.3×1.6 cm, respectively.](etm-15-05-4105-g10){#f11-etm-0-0-5970}

![Transvaginal color Doppler flow imaging and transabdominal ultrasound detection of endometrial morphology on July, 24 2014. (A) Abundant blood flow signals in the endometrium were detected. The sizes of the left and right ovary were 3.3×2.0 and 2.7×1.2 cm, respectively. (B) Endometrial thickness was 0.75 cm.](etm-15-05-4105-g11){#f12-etm-0-0-5970}

###### 

Characteristics of the included studies.

  Author, year              Country   SC source             Cell type            Study design                  Type of animal                    Mode of POF induction                                  Cell administration                                                                                                                  Follow-up duration   Outcome                                           (Refs.)
  ------------------------- --------- --------------------- -------------------- ----------------------------- --------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ -------------------- ------------------------------------------------- -----------------------
  Elfayomy, *et al*, 2016   Egypt     Human                 UCMSCs               Case-control study            Female albino Wistar rat          Paclitaxel                                             2×10^6^ 1 week after chemotherapy                                                                                                    6 weeks              FSH; E2; antral follicle count                    ([@b22-etm-0-0-5970])
  Song *et al*, 2016        China     Human                 UCMSCs               Case-control study            Female Wistar rat                 Cyclophos-phamide                                      1×10^5[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^ 5×10^4[b](#tfn2-etm-0-0-5970){ref-type="table-fn"}^ 2 weeks after chemotherapy   6 weeks              FSH; E2; antral follicle count                    ([@b23-etm-0-0-5970])
  Su *et al*, 2016          China     Sprague Dawley rats   ADSCs                Randomized controlled study   Female rat                        Tripterygium glycosides                                2×10^6^ retrograde delivery 50 days after chemotherapy                                                                               4 weeks              E2; antral follicle count; pregnancy test         ([@b24-etm-0-0-5970])
  Liu *et al*, 2016         China     Human                 OGLCs-iPSCs          Case-control study            Female C57BL/6 mouse              Cyclophos-phamide                                      5×10^8^ 1 week after chemotherapy                                                                                                    3 weeks              FSH; E2; ovarian weight; atretic follicle count   ([@b12-etm-0-0-5970])
  Zhang, *et al*, 2015      China     Human                 HAECs                Case-control study            Female C57/BL6 wild-type mouse    Busulfan and cyclophos-phamide                         2×10^6^ 1 week after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                                      4 weeks              Follicle count                                    ([@b25-etm-0-0-5970])
  Dang *et al*, 2015        China     Human                 HCMNCs               Randomized controlled study   Female nude mouse                 Gr cobalt 60 γ ([@b11-etm-0-0-5970])-ray irradiation   1×10^8^ 1 week after radiotherapy                                                                                                    4 weeks              E2; FSH; primordial follicle count                ([@b26-etm-0-0-5970])
  Lai *et al*, 2015         China     Human                 EnSCs                Case-control study            Female C57BL/6 wild-type mouse    Busulfan and cyclophos-phamide                         2×10^6^ 1 week after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                                      8 weeks              Pregnancy test                                    ([@b27-etm-0-0-5970])
  Liu *et al*, 2014         China     Human                 EnSCs                Case-control study            Female C57BL/6 mouse              Cyclophos-phamide                                      1×10^4^ 1 week after chemotherapy                                                                                                    2 weeks              FSH; E2; ovary weight                             ([@b28-etm-0-0-5970])
  Kilic *et al*, 2014       Turkey    Rats                  BMMSCs               Randomized controlled study   Female Wistar albino rat          Cyclophos-phamide                                      1.6×10^6^ 9 and 16 days after chemotherapy                                                                                           17 days              Follicle count                                    ([@b29-etm-0-0-5970])
  Liu *et al*, 2014         China     Rats                  BMMSCs               Case-control study            Female Sprague Dawley rat         Cisplatin                                              4×10^6^ 6 days after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                                      4 weeks              E2; antral follicles                              ([@b30-etm-0-0-5970])
  Lai *et al*, 2014         China     Mice                  F-SMSCs or M-SMSCs   Case-control study            Female ICR mouse                  Busulfan and cyclophos-phamide                         2×10^6^ 1 week after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                                      8 weeks              Pregnancy test                                    ([@b31-etm-0-0-5970])
  Wang *et al*, 2013        China     Human                 HAECs                Case-control study            Female C57BL/6 wild-type mouse    Busulfan and cyclophos-phamide                         2×10^6^ 1 week after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                                      8 weeks              Follicle count                                    ([@b32-etm-0-0-5970])
  Liu *et al*, 2013         China     Human                 miR-17-3p-iPS        Case-control study            Female C57BL/6 mouse              Chemoablated                                           1×10^3^ 1 week after chemotherapy                                                                                                    3 weeks              FSH; E2; ovary weight                             ([@b33-etm-0-0-5970])
  Wang *et al*, 2013        China     Human                 UCMSCs               Randomized controlled study   Female CD1 (ICR) mouse            Cyclophos-phamide                                      1×10^6^ 15 days after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                                     1 weeks                Follicle count                                  ([@b34-etm-0-0-5970])
  Fu *et al*, 2008          China       Wistar rats         BMMSCs               Randomized controlled study   Female Wistar rat                 Cyclophos-phamide                                      2×10^6^ 2 weeks after chemotherapy                                                                                                   8 weeks              FSH; E2; follicle count                           ([@b35-etm-0-0-5970])
  Lee *et al*, 2007         USA       Mice                  BMMSCs               Case-control study            Female C57BL/6 and 129/Sv mouse   Busulfan and cyclophos-phamide                         2--3×10^7^ 1 and 8 weeks after chemotherapy^[a](#tfn1-etm-0-0-5970){ref-type="table-fn"}^                                            8 weeks              Follicle count                                    ([@b36-etm-0-0-5970])

Tail intravenous injection

*in situ*. SC, stem cell; UCMSCs, human umbilical cord mesenchymal stem cells; ADSCs, adipose-derived stem cells; OGLCs-iPSCs, ovarian granulosa-like cells derived from human induced pluripotent stem cells; HAECs, human amniotic epithelial cells; HCMNCs, human cord blood mononuclear cells; EnSCs, human endometrial mesenchymal stem cells; BMMSCs, bone marrow derived mesenchymal stem cells; miR-17-3p-iPS, microRNA-17-3p-transfected human induced pluripotent stem cells; F/M-SMSCs, female/male skin-derived mesenchymal stem cells; FSH, follicle-stimulating hormone; E2, estradiol; POI, premature ovarian insufficiency; POF, premature ovarian failure; d, days;.

###### 

Subgroup analyses and meta regression for the effects of stem-cell based therapy on FSH, E2 and follicle counts in animal models of POF.

  Index/subgroup                  Studies (n)   SMD/RR (95% CI)           P-value for subgroup outcomes/interactions   I^2^ (%)   Heterogeneity P-value
  ------------------------------- ------------- ------------------------- -------------------------------------------- ---------- -----------------------
  FSH                                                                                                                             
    Delivery method                                                                                                               
      ITV                         1             −1.98 (−3.76, −0.20)      0.029                                        --         --
      Non-ITV                     7             −1.27 (−2.09, −0.45)      0.002                                        85.1       0.000
    Follow-up duration                                                                                                            
      Per week                    8             1.22 (1.18, 8.34)         0.805                                        84.7       
      Cell amount                                                                                                                 
      Per 1×10^6^                 8             1.47 (0.21, 10.1)         0.640                                        85.1       
    Units                                                                                                                         
      IU/l                        6             −1.65 (−2.60, −0.70)      0.001                                        84.4       0.000
      pg/ml                       2             −0.52 (−1.11, 0.07)       0.085                                        0.0        0.459
    Details of the animal model                                                                                                   
      Chemotherapy                7             −0.989 (−1.526, −0.452)   0.000                                        55.3       0.037
      Radiotherapy                1             −2.867 (−3.540, −2.195)   0.000                                        --         --
  Study design                                                                                                                    
      Case control                6             −1.149 (−1.735, −0.562)   0.000                                        48.3       0.085
      RCT                         2             −1.602 (−4.076, 0.873)    0.205                                        96.6       0.000
    Cell type                                                                                                                     
      UCMSCs                      3             −1.980 (−2.724, −1.236)   0.000                                        0.0        0.997
      OGLCs-iPSCs                 1             −0.685 (−1.423, 0.053)    0.069                                        --         --
      HCMNCs                      1             −2.867 (−3.540, −2.195)   0.000                                        --         --
      EnSCs                       1             −1.049 (−1.815, −0.282)   0.007                                        --         --
      miR-17-3p-iPS               1             −0.221 (−1.204, 0.763)    0.660                                        --         --
      BMMSCs                      1             −0.342 (−0.967, 0.282)    0.283                                        --         --
    Stem cell origin                                                                                                              
      Human                       7             −1.498 (−2.308, −0.687)   0.000                                        80.0       0.000
      Rat                         1             −0.342 (−0.967, 0.282)    0.283                                        --         
  E2                                                                                                                              
    Delivery method                                                                                                               
      ITV                         3             3.15 (0.34, 5.95)         0.028                                        82.6       0.003
      Non-ITV                     8             2.19 (1.01, 3.37)         0.000                                        92.1       0.000
    Follow-up duration                                                                                                            
      Per week                    11            0.76 (0.04, 12.95)        0.831                                        91.0       
    Cell amount                                                                                                                   
      Per 1×10^6^                 11            1.01 (0.06, 16.56)        0.991                                        90.8       
    Details of the animal model                                                                                                   
      Chemotherapy                10            1.877 (1.112, 2.643)      0.000                                        80.7       0.000
      Radiotherapy                1             4.990 (4.029, 5.951)      0.000                                        --         --
    Study design                                                                                                                  
      Case control                7             2.689 (1.439, 3.939)      0.000                                        82.9       0.000
      RCT                         4             1.822 (0.072, 3.573)      0.041                                        95.3       0.000
    Cell type                                                                                                                     
      UCMSCs                      4             2.683 (0.853, 4.514)      0.004                                        83.8       0.000
      ADSCs                       1             0.704 (−0.037, 1.444)     0.063                                        --         --
      OGLCs-iPSCs                 1             0.561 (−0.169, 1.292)     0.132                                        --         --
      HCMNCs                      1             4.990 (4.029, 5.951)      0                                            --         --
      EnSCs                       1             1.624 (0.791, 2.456)      0                                            --         --
      BMMSCs                      2             3.367 (−2.439, 9.174)     0.256                                        90.9       0.001
      miR-17-3p-iPS               1             2.630 (1.248, 4.011)      0                                            --         
    Stem cell origin                                                                                                              
      Human                       8             2.546 (0.310, 3.782)      0                                            90.3       0.000
      Rat                         3             1.410 (−0.002, 2.822)     0.05                                         81.9       0.004
  Follicle count                                                                                                                  
    Delivery method                                                                                                               
      ITV                         16            1.747 (0.749, 2.744)      0.001                                        88.0       0.000
      Non-ITV                     16            1.968 (1.097, 2.840)      0                                            91.6       0.000
    Follow-up duration                                                                                                            
      Per week                    32            0.93 (0.15, 5.73)         0.938                                        90.2       
    Cell amount                                                                                                                   
      Per 1×10^6^                 32            1.09 (0.14, 8.48)         0.933                                        90.3       
    Details of the animal model                                                                                                   
      Chemotherapy                31            1.670 (1.101, 2.240)      0                                            86.7       0.000
      Radiotherapy                1             7.977 (6.557, 9.397)      0                                            --         --
      Study design                                                                                                                
      Case control                21            1.489 (0.671, 2.308)      0                                            86.7       0.000
      RCT                         11            2.530 (1.420, 3.640)      0                                            93.8       0.000
    Cell type                                                                                                                     
      UCMSCs                      10            2.056 (0.989, 3.123)      0                                            72.0       0.000
      ADSCs                       1             2.678 (1.675, 3.681)      0                                            --         --
      OGLCs-iPSCs                 1             −0.649 (−1.385, 0.086)    0.084                                        --         --
      HAECs                       9             1.349 (−0.055, 2.753)     0.06                                         92.0       0.000
      HCMNCs                      1             7.977 (6.557, 9.397)      0                                            --         --
      BMMSCs                      10            1.532 (0.876, 2.188)      0                                            78.5       0.000
    Stem cell origin                                                                                                              
      Human                       21            1.884 (0.852, 2.916)      0                                            92.0       0.000
      Rat                         10            1.634 (0.943, 2.325)      0                                            82.3       0.000
      Mouse                       1             2.169 (0.431, 3.906)      0.014                                        --         --
    Follicle stage                                                                                                                
      Primordial                  6             1.93 (−0.06, 3.92)        0.057                                        95.1       0.000
      Primary                     5             1.57 (−0.16, 3.92)        0.075                                        89.9       0.000
      Secondary                   5             2.91 (0.64, 5.71)         0.012                                        91.0       0.000
      Antral                      7             2.17 (1.23, 3.10)         0                                            74.3       0.000
      Atretic                     3             −1.50 (−4.06, 1.05)       0.248                                        93.9       0.000
      Total follicles             2             4.48 (3.38, 5.58)         0                                            0          0.384
      Mature                      1             0.28 (−0.86, 1.42)        0.629                                        --         --
      Preantral                   1             1.03 (0.01, 2.04)         0.047                                        --         --
      Primordial and primary      1             2.83 (1.47, 4.20)         0                                            --         --
      Immature                    1             2.17 (0.43, 3.91)         0.014                                        --         --

ITV, intra-tail venous; RCT, randomized controlled trial; UCMSCs, human umbilical cord mesenchymal stem cells; ADSCs, adipose-derived stem cells; OGLCs-iPSCs, ovarian granulosa-like cells derived from human induced pluripotent stem cells; HAECs, human amniotic epithelial cells; HCMNCs, human cord blood mononuclear cells; EnSCs, human endometrial mesenchymal stem cells; BMMSCs, bone marrow derived mesenchymal stem cells; miR-17-3p-iPS, microRNA-17-3p-transfected human-induced pluripotent stem cells; SMD, standard mean difference; CI, confidence interval; RR, risk ratios.
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